Therapy News and Research

RSS

Researchers develop gLQ Model to determine optimal dose level, treatment schedules for high-dose radiation therapies

There is yet no straightforward way to determine the optimal dose level and treatment schedules for high-dose radiation therapies such as stereotactic radiation therapy, used to treat brain and lung cancer, or for high-dose brachytherapy for prostate and other cancers.Radiation oncologists at the Ohio State University Comprehensive Cancer Center-Arthur G. James Cancer Hospital and Richard J. Solove Research Institute may have solved the problem by developing a new mathematical model that encompasses all dose levels.

3 Sep 2010

UB symposium to discuss in silico molecular design, high-throughput screening to treat diseases

Twenty-first-century pharmaceutical breakthroughs require 21st-century drug discovery tools, such as computational or in silico molecular design and high-throughput screening of effective, new compounds. That's the theme of a University at Buffalo symposium to be held Sept. 11 on "Twenty-first Century Bioscience: In Silico Methods and High-Throughput Screening," which will feature a variety of cutting-edge advances in the field developed by researchers in Western New York and throughout the US.

3 Sep 2010

Behavioral management program for migraine sufferers boosts confidence to self-manage symptoms: Study

For severe migraine sufferers, psychological treatments build on the benefits of drug therapy, according to a new study by Elizabeth Seng and Dr. Kenneth Holroyd from Ohio University in the US.

3 Sep 2010

ImmunoCellular Therapeutics updates accomplishments in Letter to Shareholders

As the summer comes to a close, I wanted to update you on the Company's accomplishments this year, which set the stage for an exciting fall. The first eight months of the year have been very successful, with the Company attaining many of its goals, despite a very difficult economic environment, which has created challenges for many small biotechnology companies. Today, IMUC is in its best financial position ever and well positioned to validate the success it achieved in a Phase I trial for ICT-107, its dendritic cell-based cancer vaccine product candidate.

3 Sep 2010

WHO revises treatment protocols for HIV patients

Prompted by clinical research into the early initiation of antiretroviral therapies for HIV performed at the GHESKIO clinic in Port-au-Prince, Haiti, the World Health Organization (WHO) has revised its treatment protocols for HIV patients.

3 Sep 2010

New peer-reviewed study on chemopreventive effects of Protandim

LifeVantage Corporation, the maker of Protandim®, a clinically proven, science-based therapy for oxidative stress, announced today that a new peer-reviewed study involving Protandim® was published in the scientific journal PLoS ONE. The study, conducted by researchers at Louisiana State University, examined the biochemical mechanisms that underlie the ability of Protandim® to suppress tumors in mice. That ability was previously demonstrated by the authors in a study involving a mouse two-stage model of chemically-induced skin cancer.

3 Sep 2010

American Cancer Society attacks electronic cigarettes while number of users increase

The American Cancer Society continues to attack electronic cigarettes and falsely label them as dangerous and ineffective, while the number of people using the products is increasing by 20,000 to 30,000 a week. Despite the ACS's claims, e cigarette reviews by consumers are still flooding in all over the Internet that smokers who are switching to e cigarettes and e liquid are breathing, tasting, and sleeping better than they ever did while smoking traditional cigarettes.

3 Sep 2010

European Menopause and Andropause Society's position statements on post-reproductive health of women

Elsevier announced today the publication of four important position statements from the European Menopause and Andropause Society (EMAS) in the journal Maturitas on common management problems in the post-reproductive health of women. The statements cover the management of the menopause in the context of obesity, epilepsy, endometriosis and premature ovarian failure. Each statement has summary recommendations as a quick aid for the busy clinician.

3 Sep 2010

GOG to conduct Phase II trial on primary peritoneal cancer

Oncolytics Biotech Inc. announced today that the Gynecologic Oncology Group (GOG) intends to conduct a randomized Phase II trial of weekly paclitaxel versus weekly paclitaxel with REOLYSIN(R) in patients with persistent or recurrent, ovarian, fallopian tube or primary peritoneal cancer (GOG186H).

3 Sep 2010

Research on immune system can develop new therapy for inflammation, tumors

In two closely related studies, two teams of Scripps Research Institute scientists have discovered the underlying mechanisms that activate a type of immune cell in the skin and other organs. The findings may lead to the development of new therapies to treat inflammation, wounds, asthma, and malignant tumors.

3 Sep 2010

First direct evidence that X-linked TLR7 gene promotes lupus in humans

Lupus Research Institute-funded researcher Betty Tsao, PhD, at the University of California Los Angeles has discovered that humans-males in particular-with a variant form of the immune receptor gene "Toll Like Receptor 7 (TLR7)" are at increased risk of developing the autoimmune disease systemic lupus erythematosus (lupus). This breakthrough finding offers renewed hope for developing more targeted treatments.

3 Sep 2010

ISWG researchers establish guidelines for diagnosis and treatment of infantile spasms

Researchers from across the U.S., as part of the Infantile Spasms Working Group (ISWG), established guidelines for the diagnosis and treatment of infantile spasms (IS). The goal of the ISWG is to improve patient outcomes by creating protocols that educate pediatricians on early diagnosis and treatment options. Full details of this study appear online in Epilepsia, a journal published by Wiley-Blackwell on behalf of the International League Against Epilepsy.

3 Sep 2010

NEJM publishes study on Xpert MTB/RIF test for rapid molecular detection of TB and rifampin resistance

Cepheid today announced that its Xpert® MTB/RIF test was the subject of a study published in the latest edition of the New England Journal of Medicine (NEJM), "Rapid Molecular Detection of Tuberculosis and Rifampin Resistance." The complete study is now available online (http://www.nejm.org) and will appear in the September 9 print edition.

3 Sep 2010

Californians recognized for contributing to plasma protein lifesaving therapies

This month, Californians are recognized for their outstanding contributions to lifesaving therapies that treat critically ill individuals and for their donations of the blood component, plasma, that makes the creation of these unique therapies possible.

3 Sep 2010

Iroko Cardio International Sàrl announces data on HDB dosing of tirofiban, abciximab in interventional cardiology

Iroko Cardio International Sàrl announces long-term, three-year, mortality data from the Phase III, open label, multi-national study comparing high-dose bolus (HDB) dosing of AGGRASTAT(tirofiban) (25mcg/kg bolus followed by a 0.15mcg/kg/min infusion for 18-24 hours) vs. ReoPro (abciximab) in patients undergoing primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI), presented at the 2010 European Society of Cardiology Meeting in Stockholm, Sweden.

3 Sep 2010

Study shows molecular imaging benefits treatment planning for wide spectrum of cancers

A series of studies published in the September Journal of Nuclear Medicine (JNM) show that molecular imaging plays a critical role in the evaluation and treatment planning for a broad spectrum of cancers, including thyroid cancer and lymphoma.

3 Sep 2010

BAP releases new guidelines on treatments for sleep disorders

Insomnia and other sleep disorders are very common, yet are not generally well understood by doctors and other health care professionals. Now the British Association for Psychopharmacology (BAP) has released up-to-the-minute guidelines in the Journal of Psychopharmacology, published by SAGE, to guide psychiatrists and physicians caring for those with sleep problems.

3 Sep 2010

Research on motor neuron subtype may provide useful therapy for neuron diseases

Scientists have devised a method for coaxing mouse embryonic stem cells into forming a highly specific motor neuron subtype. The research, published by Cell Press in the September 3rd issue of the journal Cell Stem Cell, provides new insight into motor neuron differentiation and may prove useful for devising and testing future therapies for motor neuron diseases.

3 Sep 2010

European Commission approves MSD's MAA for SYCREST in manic episodes associated with bipolar I disorder

MSD announced today that the European Commission has approved the Marketing Authorization Application (MAA) for SYCREST® (asenapine) sublingual tablets for the treatment of moderate to severe manic episodes associated with bipolar I disorder in adults. Today's decision was based on recommendations from the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP). The Commission Decision applies to all 27 European Member States.

3 Sep 2010

Scientists develop direct method to detect gene doping

Scientists at the universities in Tübingen and Mainz have developed a test that can provide conclusive proof of gene doping. "For the first time, a direct method is now available that uses conventional blood samples to detect doping via gene transfer and is still effective if the actual doping took place up to 56 days before," Professor Perikles Simon, MD, PhD from Johannes Gutenberg University Mainz, Germany explained on Thursday.

3 Sep 2010

Therapy News and Research

Researchers develop gLQ Model to determine optimal dose level, treatment schedules for high-dose radiation therapies

UB symposium to discuss in silico molecular design, high-throughput screening to treat diseases

Behavioral management program for migraine sufferers boosts confidence to self-manage symptoms: Study

ImmunoCellular Therapeutics updates accomplishments in Letter to Shareholders

WHO revises treatment protocols for HIV patients

New peer-reviewed study on chemopreventive effects of Protandim

American Cancer Society attacks electronic cigarettes while number of users increase

European Menopause and Andropause Society's position statements on post-reproductive health of women

GOG to conduct Phase II trial on primary peritoneal cancer

Research on immune system can develop new therapy for inflammation, tumors

First direct evidence that X-linked TLR7 gene promotes lupus in humans

ISWG researchers establish guidelines for diagnosis and treatment of infantile spasms

NEJM publishes study on Xpert MTB/RIF test for rapid molecular detection of TB and rifampin resistance

Californians recognized for contributing to plasma protein lifesaving therapies

Iroko Cardio International Sàrl announces data on HDB dosing of tirofiban, abciximab in interventional cardiology

Study shows molecular imaging benefits treatment planning for wide spectrum of cancers

BAP releases new guidelines on treatments for sleep disorders

Research on motor neuron subtype may provide useful therapy for neuron diseases

European Commission approves MSD's MAA for SYCREST in manic episodes associated with bipolar I disorder

Scientists develop direct method to detect gene doping

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News